LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition

Abstract

BackgroundLASP2 (LIM and SH3 Protein 2) is a small focal adhesion protein belongs to nebulin protein family. As the newest member of nebulette family, the function of LASP2 remains to be identified.MethodsThe relationship between LASP2 expression and clinical characteristics of CRC was analyzed in 89 paraffin-embedded archived CRC specimens by immunohistochemistry (IHC). The effects of LASP2 on cell growth and migration were examined in vitro, using CCK-8 and transwell assays. Western blotting was performed to examine the impact of LASP2 on the SAPK/JNK and MAPK signaling pathways.ResultsIn the present study, we observed a decreased LASP2 expression in clinical colorectal cancer samples compared with paired normal tissues. A negative correlation was also found between LASP2 and poor prognosis of CRC patients. Gain- and loss-of-function approaches revealed that LASP2 plays inhibitory effects on the growth and migration of human CRC cells in vitro. Western-blot results showed that LASP2 could attenuate epithelial-mesenchymal transition (EMT) to accomplish its suppression on CRC aggression. In LASP2 knocked down CRC cells, EMT was inhibited along with the inactivation of JNK/p38 MAPK pathway. Consistently, treatment of JNK inhibitor (JNK inhibitor II) together with p38 inhibitor (SB203580) could resume the process of EMT. Interestingly, we found a negative relationship between LASP2 and LASP1 expression in both CRC cell lines and tumors tissues, which suggests their converse function in CRC progression.ConclusionsAll the findings indicated that LASP2 may play a significant role in suppressing CRC progression and provided a novel biomarker for CRC therapy.Electronic supplementary materialThe online version of this article (doi:10.1186/s12964-017-0179-9) contains supplementary material, which is available to authorized users.

LRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non‐small cell lung cancer

“…There is an association between LRH1 and β‐catenin, which subsequently induces intestinal cell proliferation and tumorigenesis in colon cancer . Indeed, when cancer cells activate EMT progression and obtain stem‐cell‐like potential, the likelihood of metastasis is indicated . In breast cancer, LRH1 is involved in EMT progression, and LRH1 overexpression promotes cell motility and invasion by regulating E‐cadherin and MMP9 .…”

Zyxin as a potential cancer prognostic marker promotes the proliferation and metastasis of colorectal cancer cells

“…Interestingly, although LASP2 and LASP1 share high similarity in the structure, B Wang et al (2017). detected an opposite distribution and function of LASP1 and LASP2 in CRC cells.…”

Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway

“…It has been reported that the JNK pathway activation promotes the proliferation of cancer cells by reducing the expression level of cell cycle inhibitors p16 or p21 . What's more, the JNK pathway could accelerate cancer cells migration through inducing the EMT which is accompanied with the changed expression of related proteins such as ZO‐1 and Vimentin . EMT‐like processes have been implicated in hematological malignancies in addition to solid tumors, while p38/JNK pathway was shown to be involved in portulacerebroside A‐mediated suppression of adhesion, migration and invasion in AML cell lines .…”

“…27,28 What's more, the JNK pathway could accelerate cancer cells migration through inducing the EMT which is accompanied with the changed expression of related proteins such as ZO-1 and Vimentin. 29 EMT-like processes have been implicated in hematological malignancies F I G U R E 6 PRDM5 overexpression accelerates the growth of OCI-AML leukemic xenograft tumors. A, Representative nude mice image showed the CT tumor on the left flank and the PRDM5 OE tumor on the right flank.…”